ZA200707315B - Substituted 5-phenyl pyrimidines I in therapy - Google Patents
Substituted 5-phenyl pyrimidines I in therapyInfo
- Publication number
- ZA200707315B ZA200707315B ZA200707315A ZA200707315A ZA200707315B ZA 200707315 B ZA200707315 B ZA 200707315B ZA 200707315 A ZA200707315 A ZA 200707315A ZA 200707315 A ZA200707315 A ZA 200707315A ZA 200707315 B ZA200707315 B ZA 200707315B
- Authority
- ZA
- South Africa
- Prior art keywords
- therapy
- substituted
- phenyl pyrimidines
- pyrimidines
- phenyl
- Prior art date
Links
- LVXOXXGCJHYEOS-UHFFFAOYSA-N 5-phenylpyrimidine Chemical class C1=CC=CC=C1C1=CN=CN=C1 LVXOXXGCJHYEOS-UHFFFAOYSA-N 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05001955 | 2005-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200707315B true ZA200707315B (en) | 2008-11-26 |
Family
ID=34933530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200707315A ZA200707315B (en) | 2005-01-31 | 2007-08-29 | Substituted 5-phenyl pyrimidines I in therapy |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20080146593A1 (xx) |
| EP (1) | EP1845991A2 (xx) |
| JP (1) | JP2008528535A (xx) |
| KR (1) | KR20070104893A (xx) |
| CN (1) | CN101111250A (xx) |
| AR (1) | AR054220A1 (xx) |
| AU (1) | AU2006208621B2 (xx) |
| BR (1) | BRPI0607108A2 (xx) |
| CA (1) | CA2595958A1 (xx) |
| EA (1) | EA014098B1 (xx) |
| IL (1) | IL184375A0 (xx) |
| MX (1) | MX2007008397A (xx) |
| NZ (1) | NZ556448A (xx) |
| PE (1) | PE20061042A1 (xx) |
| TW (1) | TW200637556A (xx) |
| UA (1) | UA87895C2 (xx) |
| UY (1) | UY29352A1 (xx) |
| WO (1) | WO2006079556A2 (xx) |
| ZA (1) | ZA200707315B (xx) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110144140A1 (en) * | 2006-09-07 | 2011-06-16 | Eriksen Birgitte L | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
| TW200836741A (en) * | 2007-01-11 | 2008-09-16 | Basf Ag | 2-substituted pyrimidines I in therapy |
| KR100936278B1 (ko) * | 2007-12-14 | 2010-01-13 | 한국생명공학연구원 | 단백질 포스파타제의 활성을 억제하는 피리미딘 유도체또는 이의 약학적으로 허용가능한 염을 유효성분으로함유하는 암 예방 및 치료용 조성물 |
| JP5731976B2 (ja) * | 2008-08-20 | 2015-06-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 置換ピリジン誘導体および置換ピリミジン誘導体ならびにそれらのウイルス感染の治療における使用 |
| CZ305457B6 (cs) | 2011-02-28 | 2015-09-30 | Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. | Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití |
| WO2019134082A1 (en) * | 2018-01-04 | 2019-07-11 | Wuxi Advant Biotechnology Co., Ltd. | Novel pyrimidine derivatives as mth1 inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4006235A (en) * | 1973-03-23 | 1977-02-01 | Burroughs Wellcome Co. | Treating CNS lymphoma |
| GB8314643D0 (en) * | 1983-05-26 | 1983-06-29 | Wellcome Found | Pyrimidine derivatives |
| GB9012316D0 (en) * | 1990-06-01 | 1990-07-18 | Wellcome Found | Pharmacologically active cns compounds |
| GB9700664D0 (en) * | 1997-01-14 | 1997-03-05 | British Tech Group | Anti-cancer agents |
| PL366463A1 (en) * | 2001-03-15 | 2005-02-07 | Basf Aktiengesellschaft | 5-phenylpyrimidine, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi |
| MXPA03011391A (es) * | 2001-06-12 | 2004-07-01 | Neurogen Corp | 2,5-diarilpirazinas, 2,5-diarilpiridinas y 2,5-diarilpirimidinas como moudladores de receptor crf1. |
| MXPA04004583A (es) | 2001-11-19 | 2004-08-13 | Basf Ag | 5-fenilpirimidinas, agentes que comprenden las mismas, metodo de produccion y uso de la misma. |
| JP2005523286A (ja) * | 2002-02-21 | 2005-08-04 | ビーエーエスエフ アクチェンゲゼルシャフト | ２−（２−ピリジル）−５−フェニル−６−アミノピリミジン、それを調製するための方法及び中間生成物、並びに、有害な真菌を防除するためのそれの使用 |
| ES2365011T3 (es) * | 2002-07-22 | 2011-09-20 | Orchid Research Laboratories Limited | Nuevas moléculas bioactivas. |
| US7371758B2 (en) * | 2003-03-13 | 2008-05-13 | National Science & Technology Development Agency | Antimalarial pyrimidine derivatives and methods of making and using them |
| BRPI0410482A (pt) * | 2003-05-20 | 2006-06-13 | Basf Ag | composto, processo para preparar o mesmo, agente adequado para combater fungos nocivos, e, processo para combater fungos nocivos fitopatogênicos |
| CA2532568A1 (en) * | 2003-07-24 | 2005-03-03 | Basf Aktiengesellschaft | 2-substituted pyrimidines |
| CN1871009A (zh) * | 2003-09-24 | 2006-11-29 | 惠氏控股公司 | 作为抗癌剂的5－芳基嘧啶 |
| US20050070712A1 (en) * | 2003-09-26 | 2005-03-31 | Christi Kosogof | Pyrimidine derivatives as ghrelin receptor modulators |
| DE102004003493A1 (de) * | 2004-01-23 | 2005-08-11 | Bayer Cropscience Ag | 5-Phenylpyrimidine |
| US20080132522A1 (en) * | 2004-07-14 | 2008-06-05 | Basf Aktiengesellschaft | 2-Substituted Pyrimidines, Method for Their Production and Their Use for Controlling Pathogenic Fungi |
-
2006
- 2006-01-27 TW TW095103598A patent/TW200637556A/zh unknown
- 2006-01-30 EP EP06706482A patent/EP1845991A2/en not_active Withdrawn
- 2006-01-30 CN CNA2006800035983A patent/CN101111250A/zh active Pending
- 2006-01-30 UA UAA200709766A patent/UA87895C2/ru unknown
- 2006-01-30 EA EA200701582A patent/EA014098B1/ru not_active IP Right Cessation
- 2006-01-30 MX MX2007008397A patent/MX2007008397A/es not_active Application Discontinuation
- 2006-01-30 AU AU2006208621A patent/AU2006208621B2/en not_active Ceased
- 2006-01-30 AR AR20060100329A patent/AR054220A1/es unknown
- 2006-01-30 NZ NZ556448A patent/NZ556448A/en not_active IP Right Cessation
- 2006-01-30 PE PE2006000121A patent/PE20061042A1/es not_active Application Discontinuation
- 2006-01-30 BR BRPI0607108-2A patent/BRPI0607108A2/pt not_active IP Right Cessation
- 2006-01-30 US US11/815,042 patent/US20080146593A1/en not_active Abandoned
- 2006-01-30 KR KR1020077017631A patent/KR20070104893A/ko not_active Application Discontinuation
- 2006-01-30 JP JP2007552589A patent/JP2008528535A/ja active Pending
- 2006-01-30 WO PCT/EP2006/000774 patent/WO2006079556A2/en active Application Filing
- 2006-01-30 CA CA002595958A patent/CA2595958A1/en not_active Abandoned
- 2006-01-31 UY UY29352A patent/UY29352A1/es unknown
-
2007
- 2007-07-03 IL IL184375A patent/IL184375A0/en unknown
- 2007-08-29 ZA ZA200707315A patent/ZA200707315B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ556448A (en) | 2010-12-24 |
| EP1845991A2 (en) | 2007-10-24 |
| PE20061042A1 (es) | 2006-11-20 |
| UY29352A1 (es) | 2006-08-31 |
| AU2006208621A1 (en) | 2006-08-03 |
| EA200701582A1 (ru) | 2008-02-28 |
| MX2007008397A (es) | 2007-09-07 |
| UA87895C2 (xx) | 2009-08-25 |
| TW200637556A (en) | 2006-11-01 |
| KR20070104893A (ko) | 2007-10-29 |
| BRPI0607108A2 (pt) | 2010-03-09 |
| JP2008528535A (ja) | 2008-07-31 |
| AU2006208621B2 (en) | 2011-08-11 |
| WO2006079556A3 (en) | 2006-09-21 |
| AR054220A1 (es) | 2007-06-13 |
| US20080146593A1 (en) | 2008-06-19 |
| CN101111250A (zh) | 2008-01-23 |
| CA2595958A1 (en) | 2006-08-03 |
| IL184375A0 (en) | 2007-10-31 |
| EA014098B1 (ru) | 2010-08-30 |
| WO2006079556A2 (en) | 2006-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL181433A0 (en) | Pyrimidine derivatives | |
| AP2008004486A0 (en) | Pyrimidine derivatives | |
| IL181386A0 (en) | Pyrimidine derivatives | |
| EP1724267A4 (en) | PYRIMIDINE DERIVATIVE | |
| GB0525080D0 (en) | Pyrimidine derivatives | |
| GB0525083D0 (en) | Pyrimidine derivatives | |
| IL179914A0 (en) | Pyrimidine derivatives | |
| HK1121062A1 (en) | Pyrimidine compounds | |
| GB0415364D0 (en) | Pyrimidine derivatives | |
| IL195731A0 (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| GB0517361D0 (en) | Therapeutic foam | |
| IL186939A0 (en) | Pyrimidine derivatives and their use as | |
| HK1205935A1 (en) | Non-lithotripsic kidney-stone therapy | |
| GB0525081D0 (en) | Pyrimidine derivatives | |
| GB0400700D0 (en) | Compounds useful in therapy | |
| GB0509819D0 (en) | Therapeutic foam | |
| ZA200707315B (en) | Substituted 5-phenyl pyrimidines I in therapy | |
| GB0415367D0 (en) | Pyrimidine derivatives | |
| ZA200810524B (en) | Pyrimidine derivatives useful in the treatment of cancer | |
| GB0401384D0 (en) | Compounds useful in therapy | |
| GB0424972D0 (en) | Pyrimidine compounds | |
| GB0505714D0 (en) | Improvements in sauna heating | |
| ZA200804208B (en) | Oxygen linked pyrimidine derivatives | |
| AU307129S (en) | Handbag | |
| AU307130S (en) | Handbag |